Cargando…

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

BACKGROUND: The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazarus, Rajeka, Querton, Benedicte, Corbic Ramljak, Irena, Dewasthaly, Shailesh, Jaramillo, Juan Carlos, Dubischar, Katrin, Krammer, Michael, Weisova, Petronela, Hochreiter, Romana, Eder-Lingelbach, Susanne, Taucher, Christian, Finn, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science ;, The Lancet Pub. Group 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444237/ https://www.ncbi.nlm.nih.gov/pubmed/36075233 http://dx.doi.org/10.1016/S1473-3099(22)00502-3

Ejemplares similares

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults
por: Lazarus, Rajeka, et al.
Publicado: (2022)

EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL
por: Wressnigg, N., et al.
Publicado: (2023)

Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera
por: Roques, Pierre, et al.
Publicado: (2022)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – A meeting report
por: Waheed, Dur-e-Nayab, et al.
Publicado: (2023)

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
por: Baisley, Kathy, et al.
Publicado: (2022)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
por: López-Camacho, César, et al.
Publicado: (2020)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Progress in Adenoviral Capsid-Display Vaccines
por: Vujadinovic, Marija, et al.
Publicado: (2018)

Use of adenoviral vectors as veterinary vaccines
por: Ferreira, T B, et al.
Publicado: (2005)

Adenoviral Vector Vaccines Antigen Transgene
por: Ertl, Hildegund C.J.
Publicado: (2016)

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
por: Folegatti, Pedro M, et al.
Publicado: (2022)

A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial
por: Baisley, Kathy J., et al.
Publicado: (2021)

Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity
por: Maier, Clara, et al.
Publicado: (2022)

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
por: Schneider, Martina, et al.
Publicado: (2023)

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
por: Khoury, David S., et al.
Publicado: (2023)

Repulsive Axon Guidance by Draxin Is Mediated by Protein Kinase B (Akt), Glycogen Synthase Kinase-3β (GSK-3β) and Microtubule-Associated Protein 1B
por: Meli, Rajeshwari, et al.
Publicado: (2015)

Using Multivalent Adenoviral Vectors for HIV Vaccination
por: Gu, Linlin, et al.
Publicado: (2013)

An Adenoviral Vector Based Vaccine for Rhodococcus equi
por: Giles, Carla, et al.
Publicado: (2016)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
por: Ewer, Katie, et al.
Publicado: (2017)

Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19
por: Liu, Yi, et al.
Publicado: (2023)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
por: Iheanacho, Chinonyerem O., et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine
por: Lingel, Amy, et al.
Publicado: (2017)

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors
por: Abbink, Peter, et al.
Publicado: (2018)

Adenoviral SARS vaccine induces immune responses in monkeys
Publicado: (2013)

Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
por: Kerstetter, Lucas J., et al.
Publicado: (2021)

Pandemic-response adenoviral vector and RNA vaccine manufacturing
por: Kis, Zoltán, et al.
Publicado: (2022)

The use of adenoviral vectors in gene therapy and vaccine approaches
por: Araújo, Natália Meneses, et al.
Publicado: (2022)

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
por: Farhad, Tasneem, et al.
Publicado: (2022)

Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture
Publicado: (1992)

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
por: Sayedahmed, Ekramy E., et al.
Publicado: (2020)

Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India
por: Chaudhary, Anita, et al.
Publicado: (2023)

Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins
Publicado: (1995)

Cell adhesion and migration are regulated at distinct stages of thymic T cell development: the roles of fibronectin, VLA4, and VLA5
Publicado: (1996)

ROSAT/ASCA/VLA studies of solar proxies
por: Güdel, M, et al.
Publicado: (1996)

Memory inflation following adenoviral vaccination depends on IL-21
por: Gordon, Claire L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j8doks4hi7pnfh6cmpkd1uronl